Pharma in review: trending stories 9/13/19


MD Anderson Cancer Center exec Stephen Hahn has emerged as the frontrunner for FDA commissioner. 

number2Mallinckrodt offloads BioVectra for $250 million
Mallinckrodt will sell its subsidiary, BioVectra, to an affiliate of H.I.G. Capita for $250 million.

More than half of patients with an advanced form of lung cancer initially responded to an experimental Amgen drug.


                  The U.S. FDA has granted Breakthrough Therapy designation to Novartis’ capmatinib.


Bristol-Myers said its blockbuster immunotherapy failed to meet a main goal of a late-stage trial.

Don’t miss your Daily Dose. Get news like this delivered right to your inbox.

Read More…

Leave a Reply

Your email address will not be published. Required fields are marked *